Abstract / Description of output
Aims
To assess features associated with glucagon prescribing and hospital admissions with hypoglycaemia in type one diabetes.
Methods
Observational study of 4462 adults. Outcome measures were features associated with glucagon prescriptions and predictors of hospital admissions with hypoglycaemia and high levels of glucagon prescribing.
Results
74% did not collect any glucagon prescriptions and 2.7% collected more than 6 over 3.5 years. Hospital admission with hypoglycaemia (P = 0.032), impaired awareness (P = 0.049) and female sex (P <0.001) were associated with glucagon collection. More frequent prescribing of glucagon was associated with diabetes duration (P <0.001) and socioeconomic deprivation (P <0.001). Higher average glucose (P = 0.047), higher time above 13.9mM (P = 0.008) and higher SD (P = 0.002) were associated with glucagon prescribing. Diabetes duration (P <0.001) and HbA1c (P <0.001) were higher in people with hospitalised hypoglycaemia. Higher time above 13.9mM (P = 0.004) and SD glucose (P <0.001) were most clearly associated with hospitalised hypoglycaemia.
Conclusions
A minority of people with type 1 diabetes have access to glucagon suggesting more could be done to better target this treatment. Individuals with risk factors and those with frequent glucagon prescriptions should be identified for interventions known to reduce hypoglycaemia.
To assess features associated with glucagon prescribing and hospital admissions with hypoglycaemia in type one diabetes.
Methods
Observational study of 4462 adults. Outcome measures were features associated with glucagon prescriptions and predictors of hospital admissions with hypoglycaemia and high levels of glucagon prescribing.
Results
74% did not collect any glucagon prescriptions and 2.7% collected more than 6 over 3.5 years. Hospital admission with hypoglycaemia (P = 0.032), impaired awareness (P = 0.049) and female sex (P <0.001) were associated with glucagon collection. More frequent prescribing of glucagon was associated with diabetes duration (P <0.001) and socioeconomic deprivation (P <0.001). Higher average glucose (P = 0.047), higher time above 13.9mM (P = 0.008) and higher SD (P = 0.002) were associated with glucagon prescribing. Diabetes duration (P <0.001) and HbA1c (P <0.001) were higher in people with hospitalised hypoglycaemia. Higher time above 13.9mM (P = 0.004) and SD glucose (P <0.001) were most clearly associated with hospitalised hypoglycaemia.
Conclusions
A minority of people with type 1 diabetes have access to glucagon suggesting more could be done to better target this treatment. Individuals with risk factors and those with frequent glucagon prescriptions should be identified for interventions known to reduce hypoglycaemia.
| Original language | English |
|---|---|
| Article number | 108561 |
| Journal | Journal of Diabetes and its Complications |
| Volume | 37 |
| Issue number | 9 |
| Early online date | 22 Jul 2023 |
| DOIs | |
| Publication status | E-pub ahead of print - 22 Jul 2023 |